

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT2906286

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT		
<b>CONVEYING PARTY DATA</b>			
	<b>Name</b>	<b>Execution Date</b>	
	ANDREW W. HINMAN	06/12/2014	
	DANA DAVIS	06/12/2014	
	WILLIAM D. SHRADER	06/15/2014	
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	EDISON PHARMACEUTICALS, INC.		
<b>Street Address:</b>	350 NORTH BERNARDO AVENUE		
<b>City:</b>	MOUNTAIN VIEW		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	94043		
<b>PROPERTY NUMBERS Total: 1</b>			
	<b>Property Type</b>	<b>Number</b>	
	<b>PCT Number:</b>	US2014029811	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	(650)494-0792		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	(650) 813-5715		
<b>Email:</b>	drovetti@mofo.com		
<b>Correspondent Name:</b>	ROBERT K. CERPA		
<b>Address Line 1:</b>	MORRISON & FOERSTER LLP		
<b>Address Line 2:</b>	755 PAGE MILL ROAD		
<b>Address Line 4:</b>	PALO ALTO, CALIFORNIA 94304-1018		
<b>ATTORNEY DOCKET NUMBER:</b>	526302005840		
<b>NAME OF SUBMITTER:</b>	ROBERT K. CERPA		
<b>SIGNATURE:</b>	/Robert K. Cerpa/		
<b>DATE SIGNED:</b>	06/19/2014		
<b>Total Attachments: 4</b>			
source=2005840#page1.tif			
source=2005840#page2.tif			
source=2005840#page3.tif			
source=2005840#page4.tif			

PATENT

## PATENT COOPERATION TREATY (PCT) ASSIGNMENT

This assignment is by:

1. Andrew W. HINMAN  
c/o Edison Pharmaceuticals, Inc.  
350 North Bernardo Avenue  
Mountain View, California 94043  
UNITED STATES OF AMERICA
2. Dana DAVIS  
c/o Edison Pharmaceuticals, Inc.  
350 North Bernardo Avenue  
Mountain View, California 94043  
UNITED STATES OF AMERICA
3. William D. SHRADER  
c/o Edison Pharmaceuticals, Inc.  
350 North Bernardo Avenue  
Mountain View, California 94043  
UNITED STATES OF AMERICA

(referred to in this Assignment as "Assignors"), who reside at or have a mailing address as listed above.

This Assignment is to:

Assignee: Edison Pharmaceuticals, Inc.  
Address: 350 North Bernardo Avenue, Mountain View, California 94043  
A corporation duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as "Assignee"), who desire to acquire the entire right, title and interest in said inventions and said application for letters patent of the United States, and in any United States or foreign, letters patent or patents, to be obtained therefor and thereon.

Assignors have invented certain new and useful inventions in:

PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF  
OXIDATIVE STRESS DISORDERS

for which the following PCT application has been filed.

Serial No.: PCT/US2014/29811

Filing Date: March 14, 2014

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,

1. Assignors hereby sell, assign, transfer and set over, to Assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions, Patent Cooperation Treaty (PCT) application, and any and all letters patent or patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all provisionals, national stage applications, divisions, continuations, continuations-in-part and substitutions of said application, or reissues, re-examinations or extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover for past, present and future infringement), for its own use and the use of its successors, legal representatives and assigns, to the full end of the

term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignors, had this sale and assignment not been made.

2. Assignors represent, warrant and covenant that, at the time of execution and delivery of this agreement, Assignors are the sole and lawful owners of the entire right, title and interest in and to said inventions and said application for letters patent, and that the same are unencumbered and that Assignors have good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement.


3. Assignors shall promptly sign and execute all papers and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said PCT application; (b) letters patent for said inventions in any country, including any reissue, re-examination or extension of or interference proceedings; or (c) any provisional, national stage applications, division, continuation, continuation-in-part, or substitutions of any application for letters patent or any reissues, re-examinations, extensions or interference proceedings involving any letters patent, to be obtained thereon. To be clear, for purposes of this paragraph, "desirable" shall include, without limitation, any act necessary or useful in connection with United States laws and/or international conventions.

4. Assignors hereby authorize and request the Commissioner of Patents in the United States to issue the above mentioned letters patents of the United States to Assignee as the assignee of said inventions and the letters patent to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

5. "I hereby grant Assignee's attorneys, all of Morrison & Foerster LLP, the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known."

In witness whereby, executed by the undersigned on the date(s) opposite the undersigned name(s).

Date: 12 June 2014

Signature:   
Andrew W. Hinman

Date: \_\_\_\_\_

Signature: \_\_\_\_\_  
Dana Davis

Date: \_\_\_\_\_

Signature: \_\_\_\_\_  
William D. Shradler

## PATENT COOPERATION TREATY (PCT) ASSIGNMENT

This assignment is by:

1. Andrew W. HINMAN  
c/o Edison Pharmaceuticals, Inc.  
350 North Bernardo Avenue  
Mountain View, California 94043  
UNITED STATES OF AMERICA
2. Dana DAVIS  
c/o Edison Pharmaceuticals, Inc.  
350 North Bernardo Avenue  
Mountain View, California 94043  
UNITED STATES OF AMERICA
3. William D. SHRADER  
c/o Edison Pharmaceuticals, Inc.  
350 North Bernardo Avenue  
Mountain View, California 94043  
UNITED STATES OF AMERICA

(referred to in this Assignment as "Assignors"), who reside at or have a mailing address as listed above.

This Assignment is to:

Assignee: Edison Pharmaceuticals, Inc.  
Address: 350 North Bernardo Avenue, Mountain View, California 94043  
A corporation duly organized under and pursuant to the laws of: Delaware

(referred to in this Assignment as "Assignee"), who desire to acquire the entire right, title and interest in said inventions and said application for letters patent of the United States, and in any United States or foreign, letters patent or patents, to be obtained therefor and thereon.

Assignors have invented certain new and useful inventions in:

PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF  
OXIDATIVE STRESS DISORDERS

for which the following PCT application has been filed.

Serial No.: PCT/US2014/29811

Filing Date: March 14, 2014

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,

1. Assignors hereby sell, assign, transfer and set over, to Assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions, Patent Cooperation Treaty (PCT) application, and any and all letters patent or patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all provisionals, national stage applications, divisions, continuations, continuations-in-part and substitutions of said application, or reissues, re-examinations or extensions of said letters patent or patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee (including any right to institute actions and to recover for past, present and future infringement), for its own use and the use of its successors, legal representatives and assigns, to the full end of the

term or terms for which letters patent or patents may be granted, as fully and entirely as the same would have been held and enjoyed by Assignors, had this sale and assignment not been made.

2. Assignors represent, warrant and covenant that, at the time of execution and delivery of this agreement, Assignors are the sole and lawful owners of the entire right, title and interest in and to said inventions and said application for letters patent, and that the same are unencumbered and that Assignors have good and full right and lawful authority to sell and convey the same in the manner set forth in this agreement.

3. Assignors shall promptly sign and execute all papers and documents, take all lawful oaths, and do all acts necessary, required or useful for the procurement, maintenance, enforcement, defense or otherwise to secure title thereto to the Assignee, at the sole cost and expense of Assignee, its successors, legal representatives and assigns, in each case including, without limitation, arising from or relating to (a) said inventions, or said PCT application; (b) letters patent for said inventions in any country, including any reissue, re-examination or extension of or interference proceedings; or (c) any provisional, national stage applications, division, continuation, continuation-in-part, or substitutions of any application for letters patent or any reissues, re-examinations, extensions or interference proceedings involving any letters patent, to be obtained thereon. To be clear, for purposes of this paragraph, "desirable" shall include, without limitation, any act necessary or useful in connection with United States laws and/or international conventions.

4. Assignors hereby authorize and request the Commissioner of Patents in the United States to issue the above mentioned letters patents of the United States to Assignee as the assignee of said inventions and the letters patent to be issued thereon for the sole use of Assignee, its successors, legal representatives and assigns.

5. "I hereby grant Assignee's attorneys, all of Morrison & Foerster LLP, the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office for recordation of this document, including the power to insert on this assignment the application number and filing date of said application when known."

In witness whereof, executed by the undersigned on the date(s) opposite the undersigned name(s).

Date: \_\_\_\_\_

Signature: \_\_\_\_\_  
Andrew W. Hinman

Date: 12 JUNE 2014

Signature: \_\_\_\_\_  
Dana Davis

Date: 15 June 2014

Signature: \_\_\_\_\_  
William D. Shrader